Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial

BMC Clinical Pharmacology

Wolnei Caumo²  Iraci L S Torres²  Alicia Deitos²  Izabel Cristina Custódio de Souza²  Fernando Xavier²  Caroline Buzzatti Machado¹  André Schwertner²  Joanna Ripoll Rozisky²  Gabriela Laste²  Rafael Vercelino²  Simone Azevedo de Zanette² 

[1] Pain and Palliative Care Service at the Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil;Laboratory of Pain & Neuromodulation, Institution: Hospital de Clínicas de Porto Alegre at UFRGS, Rua Ramiro Barcelos, 2350 - CEP 90035-003 Bairro Rio Branco, Porto Alegre, Brazil

关键词: Clinical trial;    BDNF;    CPM;    Amitriptyline;    Melatonin;   

Others  :  1084919
DOI  :  10.1186/2050-6511-15-40

 received in 2014-03-17, accepted in 2014-07-16,  发布年份 2014

【 摘 要 】

Background

Central disinhibition is a mechanism involved in the physiopathology of fibromyalgia. Melatonin can improve sleep quality, pain and pain threshold. We hypothesized that treatment with melatonin alone or in combination with amitriptyline would be superior to amitriptyline alone in modifying the endogenous pain-modulating system (PMS) as quantified by conditional pain modulation (CPM), and this change in CPM could be associated with serum brain-derived neurotrophic factor (BDNF). We also tested whether melatonin improves the clinical symptoms of pain, pain threshold and sleep quality.

Methods

Sixty-three females, aged 18 to 65, were randomized to receive bedtime amitriptyline (25 mg) (n = 21), melatonin (10 mg) (n = 21) or melatonin (10 mg) + amitriptyline (25 mg) (n = 21) for a period of six weeks. The descending PMS was assessed with the CPM-TASK. It was assessed the pain score on the Visual Analog Scale (VAS 0-100 mm), the score on Fibromyalgia Impact Questionnaire (FIQ), heat pain threshold (HPT), sleep quality and BDNF serum. Delta values (post- minus pre-treatment) were used to compare the treatment effect. The outcomes variables were collected before, one and six weeks after initiating treatment.

Results

Melatonin alone or in combination with amitriptyline reduced significantly pain on the VAS compared with amitriptyline alone (P < 0.01). The delta values on the VAS scores were-12.85 (19.93),-17.37 (18.69) and-20.93 (12.23) in the amitriptyline, melatonin and melatonin+amitriptyline groups, respectively. Melatonin alone and in combination increased the inhibitory PMS as assessed by the Numerical Pain Scale [NPS_(0-10)] reduction during the CPM-TASK:-2.4 (2.04) melatonin + amitriptyline,-2.65 (1.68) melatonin, and-1.04 (2.06) amitriptyline, (P < 0.05). Melatonin + amitriptyline treated displayed better results than melatonin and amitriptyline alone in terms of FIQ and PPT improvement (P < 0.05, fort both).

Conclusion

Melatonin increased the inhibitory endogenous pain-modulating system as assessed by the reduction on NPS_(0-10) during the CPM-TASK. Melatonin alone or associated with amitriptyline was better than amitriptyline alone in improving pain on the VAS, whereas its association with amitriptyline produced only marginal additional clinical effects on FIQ and PPT.

Trial registration

Current controlled trail is registered at clinical trials.gov upon under number NCT02041455. Registered January 16, 2014.

【 授权许可】

   
2014 de Zanette et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ: Fibromyalgia syndrome. J Rheumatol 2005, 32:2270-2277.
• [2]Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV: Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006, 67:1219-1225.
• [3]Wikner J, Hirsch U, Wetterberg L, Röjdmark S: Fibromyalgia–a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf) 1998, 49:179-183.
• [4]Bennett RM: The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002, 28:181-199. v
• [5]Citera G, Arias MA, Maldonado-Cocco JA, Lázaro MA, Rosemffet MG, Brusco LI, Scheines EJ, Cardinalli DP: The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000, 19:9-13.
• [6]Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI: Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011, 50:267-271.
• [7]Mahdi AA, Fatima G, Das SK, Verma NS: Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys 2011, 48:82-87.
• [8]Laste G, Vidor L, de Macedo IC, Rozisky JR, Medeiros L, de Souza A, Meurer L, de Souza IC, Torres IL, Caumo W: Melatonin treatment entrains the rest-activity circadian rhythm in rats with chronic inflammation. Chronobiol Int 2013, 30:1077-1088.
• [9]Detanico BC, Piato AL, Freitas JJ, Lhullier FL, Hidalgo MP, Caumo W, Elisabetsky E: Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur J Pharmacol 2009, 607:121-125.
• [10]Caumo W, Levandovski R, Hidalgo MP: Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J Pain 2009, 10:100-108.
• [11]Laste G, de Macedo IC, Ripoll Rozisky J, Ribeiro da Silva F, Caumo W, Torres IL: Melatonin administration reduces inflammatory pain in rats. J Pain Res 2012, 5:359-362.
• [12]Ambriz-Tututi M, Granados-Soto V: Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 2007, 132:273-280.
• [13]Esposito E, Cuzzocrea S: Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010, 8:228-242.
• [14]Caumo W, Torres F, Moreira NL, Auzani JA, Monteiro CA, Londero G, Ribeiro DF, Hidalgo MP: The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2007, 105:1263-1271. table of contents
• [15]Vidor LP, Torres IL, Custódio de Souza IC IC, Fregni F, Caumo W: Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study. J Pain Symptom Manage 2013, 46:422-432.
• [16]Schwertner A, Conceição Dos Santos CC, Costa GD, Deitos A, de Souza A, de Souza IC, Torres IL, da Cunha Filho JS, Caumo W: Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial. Pain 2013, 154:874-881.
• [17]Yarnitsky D: Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Curr Opin Anaesthesiol 2010, 23:611-615.
• [18]Paul-Savoie E, Marchand S, Morin M, Bourgault P, Brissette N, Rattanavong V, Cloutier C, Bissonnette A, Potvin S: Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol J 2012, 6:296-302.
• [19]Houvenagel E, Forzy G, Leloire O, Gallois P, Hary S, Hautecoeur P, Convain L, Henniaux M, Vincent G, Dhondt JL: Cerebrospinal fluid monoamines in primary fibromyalgia]. Rev Rhum Mal Osteoartic 1990, 57:21-23.
• [20]Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, Gomeni C: Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H] imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 2001, 40:290-296.
• [21]Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
• [22]Wood PB, Glabus MF, Simpson R, Patterson JC: Changes in gray matter density in fibromyalgia: correlation with dopamine metabolism. J Pain 2009, 10:609-618.
• [23]Potvin S, Larouche A, Normand E, de Souza JB, Gaumond I, Grignon S, Marchand S: DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J Pain 2009, 10:969-975.
• [24]Volz MS, Medeiros LF, Tarragô MG, Vidor LP, Dall’Agnol L, Deitos A, Brietzke A, Rozisky JR, Rispolli B, Torres IL, Fregni F, Caumo W: The relationship between cortical excitability and pain catastrophizing in myofascial pain. J Pain 2013, 14:1140-1147.
• [25]Millan MJ: Descending control of pain. Prog Neurobiol 2002, 66:355-474.
• [26]Stefani L, Muller S, Torres I, Razzolini B, Rozisky J, Fregni F, Markus R, Caumo W: A Phase II, randomized, double-blind, placebo controlled, dose–response trial of the melatonin effect on the pain threshold of healthy subjects. PLoS One 2013, 8(10):e74107.27.
• [27]Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ: Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol 2012, 63:641-647.
• [28]Golombek DA, Escolar E, Burin LJ, De Brito Sánchez MG, Cardinali DP: Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur J Pharmacol 1991, 194:25-30.
• [29]Schulz KF, Altman DG, Moher D, Group C: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg 2011, 9:672-677.
• [30]Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62:600-610.
• [31]Scott J, Huskisson EC: Graphic representation of pain. Pain 1976, 2:175-184.
• [32]Couto C, de Souza IC, Torres IL, Fregni F, Caumo W: Paraspinal stimulation combined with trigger point needling and needle rotation for the treatment of myofascial pain: a randomized sham-controlled clinical trial. Clin J Pain 2014, 30:214-223.
• [33]Dao TT, Lavigne GJ, Feine JS, Tanguay R, Lund JP: Power and sample size calculations for clinical trials of myofascial pain of jaw muscles. J Dent Res 1991, 70:118-122.
• [34]Kaipper MB, Chachamovich E, Hidalgo MP, Torres IL, Caumo W: Evaluation of the structure of Brazilian State-Trait Anxiety Inventory using a Rasch psychometric approach. J Psychosom Res 2010, 68:223-233.
• [35]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [36]Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
• [37]Lobbestael J, Leurgans M, Arntz A: Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother 2011, 18:75-79.
• [38]Sehn F, Chachamovich E, Vidor LP, Dall-Agnol L, de Souza IC, Torres IL, Fregni F, Caumo W: Cross-cultural adaptation and validation of the Brazilian Portuguese version of the pain catastrophizing scale. Pain Med 2012, 13:1425-1435.
• [39]Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
• [40]Marques A, Santos A, Assumpcao A, Matsutani L, Lage L, Pereira C: Validation of a Brazilian version of the Fibromyalgia Impact Questionnaire (FIQ). Ann Rheum Dis 2006, 65:557-557.
• [41]Fischer AA: Pressure algometry over normal muscles. Standard values, validity and reproducibility of pressure threshold. Pain 1987, 30:115-126.
• [42]Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S: An experimental model to measure excitatory and inhibitory pain mechanisms in humans. Brain Res 2008, 1230:73-79.
• [43]Magerl W, Krumova EK, Baron R, Tölle T, Treede RD, Maier C: Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 2010, 151:598-605.
• [44]Marchand S, Arsenault P: Spatial summation for pain perception: interaction of inhibitory and excitatory mechanisms. Pain 2002, 95:201-206.
• [45]Schestatsky P, Valls-Solé J, Costa J, León L, Veciana M, Chaves ML: Skin autonomic reactivity to thermoalgesic stimuli. Clin Auton Res 2007, 17:349-355.
• [46]Tesarz J, Gerhardt A, Schommer K, Treede RD, Eich W: Alterations in endogenous pain modulation in endurance athletes: an experimental study using quantitative sensory testing and the cold-pressor task. Pain 2013, 154:1022-1029.
• [47]Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 1989, 27:S178-S189.
• [48]Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I: Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011, 51:270-277.
• [49]Mantovani M, Kaster MP, Pertile R, Calixto JB, Rodrigues AL, Santos AR: Mechanisms involved in the antinociception caused by melatonin in mice. J Pineal Res 2006, 41:382-389.
• [50]Basbaum AI, Fields HL: Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984, 7:309-338.
• [51]Gebhart GF: Descending modulation of pain. Neurosci Biobehav Rev 2004, 27:729-737.
• [52]Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends Neurosci 2002, 25:319-325.
• [53]Hadjipavlou G, Dunckley P, Behrens TE, Tracey I: Determining anatomical connectivities between cortical and brainstem pain processing regions in humans: a diffusion tensor imaging study in healthy controls. Pain 2006, 123:169-178.
• [54]Schwenkreis P, Janssen F, Rommel O, Pleger B, Völker B, Hosbach I, Dertwinkel R, Maier C, Tegenthoff M: Bilateral motor cortex disinhibition in complex regional pain syndrome (CRPS) type I of the hand. Neurology 2003, 61:515-519.
• [55]Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL: Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum 2012, 64:2907-2916.
• [56]Delafoy L, Gelot A, Ardid D, Eschalier A, Bertrand C, Doherty AM, Diop L: Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. Gut 2006, 55:940-945.
• [57]Groth R, Aanonsen L: Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia. Pain 2002, 100:171-181.
• [58]Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004, 361:184-187.
• [59]Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, Shelton DB, McMahon SB, Thompson SW: Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999, 19:5138-5148.
• [60]Genoud C, Knott GW, Sakata K, Lu B, Welker E: Altered synapse formation in the adult somatosensory cortex of brain-derived neurotrophic factor heterozygote mice. J Neurosci 2004, 24:2394-2400.
• [61]Rutherford LC, DeWan A, Lauer HM, Turrigiano GG: Brain-derived neurotrophic factor mediates the activity-dependent regulation of inhibition in neocortical cultures. J Neurosci 1997, 17:4527-4535.
• [62]Ortega E, García JJ, Bote ME, Martín-Cordero L, Escalante Y, Saavedra JM, Northoff H, Giraldo E: Exercise in fibromyalgia and related inflammatory disorders: known effects and unknown chances. Exerc Immunol Rev 2009, 15:42-65.
• [63]Bote ME, García JJ, Hinchado MD, Ortega E: Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 2012, 19:343-351.
• [64]Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001, 40:743-749.
• [65]Bilici D, Akpinar E, Kiziltunç A: Protective effect of melatonin in carrageenan-induced acute local inflammation. Pharmacol Res 2002, 46:133-139.
• [66]Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabó C: Protective effect of melatonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 1997, 23:106-116.
• [67]Morgan P, Barrett P, Howell H, Helliwell R: Melatonin receptors - localization, molecular pharmacology and physiological significance. Neurochem Int 1994, 24:101-146.
• [68]Noseda R, Hernández A, Valladares L, Mondaca M, Laurido C, Soto-Moyano R: Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT2 receptor-dependent. Neurosci Lett 2004, 360:41-44.
• [69]Li SR, Wang T, Wang R, Dai X, Chen Q, Li RD: Melatonin enhances antinociceptive effects of delta-, but not mu-opioid agonist in mice. Brain Res 2005, 1043:132-138.
• [70]Bazzichi L, Rossi A, Giacomelli C, Bombardieri S: Exploring the abyss of fibromyalgia biomarkers. Clin Exp Rheumatol 2010, 28:S125-S130.
• [71]Yunus MB: Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007, 36:339-356.
• [72]Yunus MB: Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007, 21:481-497.
• [73]Fives AW, Russell D, Kearns N, Rena Lyons G, Eaton P, Canavan J, Devaney C, O’Brien A: The role of random allocation in randomized controlled trials: distinguishing selection bias from baseline imbalance. J Multidisciplinary Eval 2013, 9:33-42.
• [74]Pernambuco AP, Schetino LP, Viana RS, Carvalho LS, Reis D: The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 2014, in press. in press
• [75]Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
• [76]Cazzola M: Application of Number Needed to Treat (NNT) as a Measure of Treatment Effect in Respiratory Medicine. Treat Respir Med 2006, 5:79-84.
• [77]Plesh O, Curtis D, Levine J, McCall WD: Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil 2000, 27:834-841.
• [78]Bendtsen L, Jensen R: Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000, 20:603-610.